Francesco Cosentino

About me
Publications
Public outreach and news

About me

Francesco Cosentino is a Senior Physician and a Professor of Clinical Cardiovascular Research. His research is about trying to understand the molecular mechanisms behind increased risk of cardiovascular disease linked to diabetes, overweight, and aging. The research ranges from the laboratory bench to clinical trials.

Articles

Journal article: EUROPEAN HEART JOURNAL. 2025;:ehaf520
Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids
Landmesser U; Thum T; Tokgozoglu L; Guzik TJ; Cosentino F; Hajjar R; Goncalves A; Laguna-Fernandez A; Nioi P; Prochaska JH; Rocha R; Kathiresan S; Marz J; Maurer MS; O'Donnell CJ; Passacquale G; Tavridou A; Van Heetvelde M; Himmelmann A; Meder B; Roessig L; Crea F; Luscher TF
Journal article: EUROPEAN HEART JOURNAL. 2025;46(28):2776-2779
The year in cardiovascular medicine 2024: the top 10 papers in diabetes and metabolic disorders
Cosentino F; Cannon CP; Marx N
Journal article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2025;39(7):109045
Obesity and its management in primary care setting
Ibrahim M; Ba-Essa EM; Alvarez JA; Baker J; Bruni V; Cahn A; Ceriello A; Cosentino F; Davies MJ; De Domenico F; Eckel RH; Friedman AN; Goldney J; Hamtzany O; Isaacs S; Karadeniz S; Leslie RD; Lingvay I; McLaughlin S; Mobarak O; Del Prato S; Prattichizzo F; Rizzo M; Roetzer RD; le Roux CW; Schnell O; Seferovic PM; Somers VK; Standl E; Thomas A; Tuccinardi D; Valensi P; Umpierrez GE
Article: ESC HEART FAILURE. 2025;12(2):900-911
Phenotyping patients with chronic obstructive pulmonary disease and heart failure
Becher PM; Lindberg F; Benson L; Hage C; Dahlstrom U; Rosenkranz S; Cosentino F; Rosano GMC; Blankenberg S; Kirchhof P; Braunschweig F; Lund LH; Savarese G
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2025;27(3):521-526
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
Pandey A; Kolkailah AA; Mcguire DK; Frederich RC; Cater NB; Cosentino F; Pratley RE; Dagogo-Jack S; Cherney DZI; Wynant W; Gantz I; Mancuso JP; Masiukiewicz U; Cannon CP
Article: DIABETES OBESITY & METABOLISM. 2025;27(2):583-594
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
Cosentino F; Dagogo-Jack S; Frederich R; Cannon CP; Cherney DZI; Mancuso JP; Wynant W; Xing A; Gantz I; Cater NB; Pratley RE
Article: KIDNEY DISEASES. 2025;11(1):63-74
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial
Cherney DZI; Frederich R; Pratley RE; Cosentino F; Dagogo-Jack S; Pong A; Gantz I; Cater NB; Mancuso JP; Masiukiewicz U; Cannon CP
Article: EUROPEAN HEART JOURNAL. 2024;45(48):5117-5126
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction
Marx N; Ryden L; Federici M; Marx-Schuett K; Verket M; Mueller-Wieland D; Gerstein HC; Chan J; Cosentino F; Holman RR; Mellbin L; Ray KK; Standl E; Verma S; Wood D; Tuomilehto J; De Caterina R
Article: EUROPEAN HEART JOURNAL. 2024;45(48):5171-5185
The inflammatory and oxidative phenotype of gestational diabetes is epigenetically transmitted to the offspring: role of methyltransferase MLL1-induced H3K4me3
Di Pietrantonio N; Sanchez-Ceinos J; Shumliakivska M; Rakow A; Mandatori D; Di Tomo P; Formoso G; Bonfini T; Baldassarre MPA; Sennstrom M; Almahmeed W; Pandolfi A; Cosentino F
Article: DIABETES OBESITY & METABOLISM. 2024;26(11):5336-5346
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
Sridhar VS; Cosentino F; Dagogo-Jack S; Mcguire DK; Pratley RE; Cater NB; Noyes Essex M; Mancuso JP; Zhao Y; Cherney DZI
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2024;26(9):1893-1903
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases
Seferovic PM; Paulus WJ; Rosano G; Polovina M; Petrie MC; Jhund PS; Tschoepe C; Sattar N; Piepoli M; Papp Z; Standl E; Mamas MA; Valensi P; Linhart A; Lalic N; Ceriello A; Doehner W; Ristic A; Milinkovic I; Seferovic J; Cosentino F; Metra M; Coats AJS
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2024;10(4):296-306
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries
Wallner M; Biber ME; Stolfo D; Sinagra G; Benson L; Dahlstrom U; Gudbjornsdottir S; Cosentino F; Mol PGM; Rosano GMC; Butler J; Metra M; Lund LH; Ferrannini G; Savarese G
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2024;211:111666
Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases - Recommendations from the taskforce of the guideline workshop
Gavin JR; Rodbard HW; Battelino T; Brosius F; Ceriello A; Cosentino F; Giorgino F; Green J; Ji L; Kellerer M; Koob S; Kosiborod M; Lalic N; Marx N; Nedungadi TP; Parkin CG; Topsever P; Ryden L; Sheu WH-H; Standl E; Vandvik PO; Schnell O
Article: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):122
Repressive H3K27me3 drives hyperglycemia-induced oxidative and inflammatory transcriptional programs in human endothelium
Sanchez-Ceinos J; Hussain S; Khan AW; Zhang L; Almahmeed W; Pernow J; Cosentino F
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2024;208:111112
Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome
Savonitto S; Morici N; Pancani S; Nozza A; Cosentino F; Filardi PP; Cavallini C; Angeli F; Stahli BE; Heerspink HJL; Mannini A; Schwartz GG; Lincoff AM; Tardif J-C; Grobbee DE
Article: EUROPEAN HEART JOURNAL. 2023;44(48):5163-5166
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial
Pandey A; Kolkailah AA; Cosentino F; Cannon CP; Frederich RC; Cherney DZI; Dagogo-Jack S; Pratley RE; Cater NB; Gantz I; Mancuso JP; McGuire DK
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.3235
Epigenetically-driven persistence of inflammatory and oxidative phenotypes in adolescents born to women with gestational diabetes
Ceinos JS; Di Pietrantonio N; Shumliakivska M; Rakow A; Mandatori D; Di Tomo P; Formoso G; Bonfini T; Baldassarre MPA; Sennstrom M; Almahmeed W; Pandolfi A; Cosentino F
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.3056
Epigenetic control of inflammation by histone methylation in cardiometabolic heart failure with preserved ejection fraction
Costantino S; Ambrosini S; Mohammed SA; Gorica E; Akhmedov A; Cosentino F; Ruschitzka F; Paneni F
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.3055
Role of methyltransferase Set7 in obesity-related endothelial activation: functions beyond histone methylation
Ceinos JS; Dottling P; Jakobsson ME; Vegvari A; Cosentino F
Journal article: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2023;34(11S):854-855
Effects of Ertugliflozin by Uric Acid Quintile: Observations from VERTIS CV
Sridhar V; Cosentino F; Dagogo-Jack S; Pratley RE; Cater NB; Essex MN; Maldonado M; Zhao Y; Cherney D
Article: JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY. 2023;17(6):1698-1710
Guideline Development for Medical Device Technology: Issues for Consideration
Battelino T; Brosius F; Ceriello A; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Lalic N; Marx N; Nedungadi TP; Ryden L; Rodbard HW; Ji L; Sheu WH-H; Standl E; Parkin CG; Schnell O
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2023;108(8):2042-2051
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Dagogo-Jack S; Frederich R; Liu J; Cannon CP; Shi H; Cherney DZI; Cosentino F; Masiukiewicz U; Gantz I; Pratley RE
Article: KIDNEY INTERNATIONAL REPORTS. 2023;8(4):746-753
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial
Cherney DZI; Cosentino F; McGuire DK; Kolkailah AA; Dagogo-Jack S; Pratley RE; Frederich R; Maldonado M; Liu C-C; Cannon CP
Article: LANCET HEALTHY LONGEVITY. 2023;4(4):e143-e154
Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial
Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
Journal article: KIDNEY INTERNATIONAL REPORTS. 2023;8(3):s191-s192
WCN23-0356 HYPOGLYCEMIA AND KIDNEY EVENTS IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
Cherney D; Cosentino F; Pratley RE; Dagogo-Jack S; McGuire DK; Maldonado M; Frederich R; Fu W
Article: DIABETES OBESITY & METABOLISM. 2023;25(3):758-766
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin
Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Frederich R; Liu J; Pong A; Lin J; Cater NB; Pratley RE
Journal article: DUBAI DIABETES AND ENDOCRINOLOGY JOURNAL. 2023;29(2):67-88
Cardiometabolic Guidelines: Cardiovascular Risk Assessment and Management in Patients with Dysglycemia
Hassanein M; Sabbour H; Al Awadi F; Abusnana S; Afandi B; Al Kaabi J; Bashier A; Cosentino F; Tamimi HE; Farghali M; Farooqi MH; Hafidh K; Heshmat H; Hijazi R; Jabbar A; Kenz S; Nour SE; Shehab A; Shook J; Suliman M; Zaky H; Almahmeed W
Journal article: COR ET VASA. 2022;64:31-38
The year in cardiovascular medicine 2021 diabetes and metabolic disorders
Aschermann M
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2022;9(1):10-17
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
Article: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2022;1868(12):166559
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health
Lo Presti E; Nuzzo D; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kalra S; Kapoor N; Kempler P; Lessan N; Lotufo P; Papanas N; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Article: MED. 2022;3(11):735-739
One size fits all: The story of SGLT2 inhibitors in heart failure
Verma S; Dhingra NK; Bhatt DL; Marx N; Cosentino F
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(15):1945-1954
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Kerneis M; Cosentino F; Ferrari R; Georges J-L; Kosmachova E; Laroche C; Maggioni AP; Rittger H; Steg PG; Maczynska J; Tavazzi L; Valgimigli M; Gale CP; Komajda M
Article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2022;36(11):108336
Post-COVID syndrome, inflammation, and diabetes
Rizvi AA; Kathuria A; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Galia M; Goh S-Y; Janez A; Kalra S; Kempler P; Lessan N; Lotufo P; Papanas N; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Journal article: EUROPEAN HEART JOURNAL. 2022;43(Supplement_2):ehac544.962
Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial
Pandey A; Kolkailah AA; Cosentino F; Cannon CP; Frederich R; Cherney DZI; Dagogo-Jack S; Pratley RE; Cater NB; Gantz I; Mancuso JP; McGuire DK
Journal article: EUROPEAN HEART JOURNAL. 2022;43(Supplement_2):ehac544.2883
A chromatin mark by SETD7 regulates myocardial inflammation in obesity-related heart failure with preserved ejection fraction
Costantino S; Ambrosini S; Mohammed SA; Gorica E; Akhmedov A; Cosentino F; Ruschitzka F; Hamdani N; Paneni F
Article: DIABETES OBESITY & METABOLISM. 2022;24(9):1829-1839
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
Segar MW; Kolkailah AA; Frederich R; Pong A; Cannon CP; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Liu C-C; Maldonado M; Liu J; Cater NB; Pandey A; Cherney DZI
Article: KIDNEY INTERNATIONAL REPORTS. 2022;7(8):1782-1792
Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial
Cherney DZI; Dagogo-Jack S; Cosentino F; Pratley RE; Frederich R; Maldonado M; Liu C-C; Cannon CP; VERTIS CVI
Article: JOURNAL OF CARDIAC FAILURE. 2022;28(7):1050-1062
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; Mcmurray JJV; Dahlstrom U; Lund LH; Savarese G
Article: DIABETES OBESITY & METABOLISM. 2022;24(7):1245-1254
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
Journal article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(13):7326
The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel
Jensterle M; Herman R; Janez A; Mahmeed WA; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Galia M; Goh S-Y; Kalra S; Kempler P; Lessan N; Lotufo P; Papanas N; Rizvi AA; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Article: DIABETES OBESITY & METABOLISM. 2022;24(6):1114-1122
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
Cherney DZI; Cosentino F; Pratley RE; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu C-C; Cannon CP
Article: DIABETES THERAPY. 2022;13(4):795-810
Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
Janic M; Rizzo M; Cosentino F; Pantea Stoian A; Lunder M; Sabovic M; Janez A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(1):5-115
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Visseren FLJ; Mach F; Smulders YM; Carballo D; Koskinas KC; Bäck M; Benetos A; Biffi A; Boavida J-M; Capodanno D; Cosyns B; Crawford C; Davos CH; Desormais I; Di Angelantonio E; Franco OH; Halvorsen S; Hobbs FDR; Hollander M; Jankowska EA; Michal M; Sacco S; Sattar N; Tokgozoglu L; Tonstad S; Tsioufis KP; van Dis I; van Gelder IC; Wanner C; Williams B; ESC Scientific Document Group
Article: EUROPEAN HEART JOURNAL. 2022;43(4):263-270
The year in cardiovascular medicine 2021: diabetes and metabolic disorders
Cosentino F; Bhatt DL; Marx N; Verma S
Article: AMERICAN JOURNAL OF NEPHROLOGY. 2022;53(7):516-525
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley RE; Frederich R; Maldonado M; Liu C-C; Pong A; Cannon CP
Article: FRONTIERS IN CARDIOVASCULAR MEDICINE. 2021;8:787761
Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel
Al Mahmeed W; Al-Rasadi K; Banerjee Y; Ceriello A; Cosentino F; Galia M; Goh S-Y; Kempler P; Lessan N; Papanas N; Rizvi AA; Santos RD; Stoian AP; Toth PP; Rizzo M
Journal article: CIRCULATION. 2021;144(Suppl_1):a9341
Abstract 9341: Hepatic Steatosis Index and Fibrosis-4 Scores in Patients With Type 2 Diabetes - Post Hoc Analyses from VERTIS CV
Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZ; Cosentino F; McGuire DK; Shih WJ; Frederich R; Liu J; Lin J; Cater NB; Pratley RE
Journal article: EUROPEAN HEART JOURNAL. 2021;42(Supplement_1):ehab724.2650
Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial
Cosentino F; Cannon CP; Cherney DZI; Dagogo-Jack S; Pratley RE; Charbonnel B; Shih WJ; Mancuso JP; Maldonado M; Frederich R; Cater NB; Wang S; McGuire DK
Journal article: EUROPEAN HEART JOURNAL. 2021;42(Supplement_1):ehab724.2649
Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
Segar MW; Pandey A; Cherney DZI; Cannon CP; Cosentino F; Dagogo-Jack S; Pratley RE; Shih WJ; Frederich R; Cater NB; Maldonado M; Liu J; Liu C; Pong A; McGuire DK
Journal article: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32(10S):262-263
Effects of Ertugliflozin on Kidney End Points in Patients with Non-Albuminuric Diabetic Kidney Disease in VERTIS CV
Cherney D; Dagogo-Jack S; Cosentino F; Mcguire DK; Pratley RE; Frederich R; Maldonado M; Liu C-C; Cannon CP
Article: BMJ OPEN DIABETES RESEARCH & CARE. 2021;9(1):e002484
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
Article: CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;16(9):1345-1354
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial
Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu C-C; Liu J; Pong A; Cannon CP
Article: CLINICAL CARDIOLOGY. 2021;44(8):1139-1143
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials
Cherney DZI; Dagogo-Jack S; McGuire DK; Cosentino F; Pratley R; Shih WJ; Frederich R; Maldonado M; Liu J; Wang S; Cannon CP
Journal article: COR ET VASA. 2021;63:52-61
The year in cardiovascular medicine 2020: epidemiology and prevention (Reprinted from Eur Heart J, vol 42, pg 813-821, 2021)
Estruch R; Ruilope LM; Cosentino F
Article: DIABETOLOGIA. 2021;64(6):1256-1267
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2021;23(6):1012-1022
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlstrom U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2021;28(4):432-445
Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries The ESC EORP CICD-LT registry
Komajda M; Cosentino F; Ferrari R; Kerneis M; Kosmachova E; Laroche C; Maggioni AP; Rittger H; Steg PG; Szwed H; Tavazzi L; Valgimigli M; Gale CP
Journal article: KIDNEY INTERNATIONAL REPORTS. 2021;6(4):s154-s155
POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV
Cherney D; Charbonnel B; Cosentino F; Pratley RE; Dagogo-Jack S; Shih WJ; McGuire DK; Frederich R; Maldonado M; Liu J; Pong A; Liu C; Cannon CP
Article: EUROPEAN HEART JOURNAL. 2021;42(8):813-821
The year in cardiovascular medicine 2020: epidemiology and prevention
Estruch R; Ruilope LM; Cosentino F
Article: JAMA CARDIOLOGY. 2021;6(2):148-158
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2021;7(1):28-33
The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry
Komajda M; Cosentino F; Ferrari R; Laroche C; Maggioni A; Steg PG; Tavazzi L; Kerneis M; Valgimigli M; Gale CP
Article: CIRCULATION. 2020;142(23):2205-2215
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2020;22(11):1984-1986
Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure (an update on the sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)
Seferovic PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Cavusoglu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferovic J; Jhund PS; Dattilo G; Celutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainscak M; Jankowska E; Mueller C; Cosentino F; Lund LH; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Article: CIRCULATION RESEARCH. 2020;127(10):1261-1273
Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD
Hussain S; Khan AW; Akhmedov A; Suades R; Costantino S; Paneni F; Caidahl K; Mohammed SA; Hage C; Gkolfos C; Bjorck H; Pernow J; Lund LH; Luscher TF; Cosentino F
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;383(15):1425-1435
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Cannon CP; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Masiukiewicz U; Charbonnel B; Frederich R; Gallo S; Cosentino F; Shih WJ; Gantz I; Terra SG; Cherney DZI; McGuire DK
Journal article: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2020;31(10S):b5-b6
Effect of Ertugliflozin on Initial eGFR Decline and Chronic Slope: Analyses from the VERTIS CV Trial
Cherney D; Charbonnel B; Cosentino F; Pratley RE; Dagogo-Jack S; Shih WJ; Mcguire DK; Frederich R; Maldonado M; Liu J; Pong A; Liu C-C; Cannon CP
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2020;22(9):1495-1503
Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Seferovic PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Cavusoglu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferovic J; Jhund PS; Dattilo G; Celutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainscak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Article: HEART. 2020;106(17):1357-1364
Diabetes and coronary artery disease: not just a risk factor
Grant PJ; Cosentino F; Marx N
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2020;313:76-82
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design
Savarese G; Settergren C; Schrage B; Thorvaldsen T; Lofman I; Sartipy U; Mellbin L; Meyers A; Farsani SF; Brueckmann M; Brodovicz KG; Vedin O; Asselbergs FW; Dahlstrom U; Cosentino F; Lund LH
Article: DIABETES STOFFWECHSEL UND HERZ. 2020;29(3):164-170
Proceedings of the Guideline Workshop 2019-Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases
Marx N; Ryden L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi P; Rodbard HW; Vandvik PO; Standl E; Schnell O
Journal article: RUSSIAN JOURNAL OF CARDIOLOGY. 2020;25(4):3839
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds/Leeds Teaching Hospitals NHS Trust, LIGHT Laboratories, Clarendon Way
Cosentino F; Grant PJ; Aboyans V; Bailey GJ; Ceriello А; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TВ; Huikuri HV; Johansson I; Jüni P; Lettino M; Marx N; Mellbin LG; Östgren CJ; Rocca B; Roffi M; Sattar N; Seferović PM; Sousa-Uva M; Valensi P; Wheeler DC
Article: REVISTA ESPANOLA DE CARDIOLOGIA. 2020;73(5):404.e1-404.e59
Clinical Practice Guides ESC 2019 guide on diabetes, prediabetes and cardiovascular disease, in collaboration with the European Association for the Study of Diabetes (EASD)
Cosentino F; Grant PJ; Aboyans V; Bailey CJ; Ceriello A; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TB; Huikuri HV; Johansson I; Juni P; Lettino M; Marx N; Mellbin LG; Ostgren CJ; Rocca B; Roffi M; Sattar N; Seferovic PM; Sousa-Uva M; Valensi P; Wheeler DC
Article: EUROPEAN HEART JOURNAL. 2020;41(15):1514-1519
High-intensity interval training modulates retinal microvascular phenotype and DNA methylation of p66^Shc gene: a randomized controlled trial (EXAMIN AGE)
Streese L; Khan AW; Deiseroth A; Hussain S; Suades R; Tiaden A; Kyburz D; Cosentino F; Hanssen H
Journal article: SA HEART JOURNAL. 2020;17(1):20-28
The year in cardiology: cardiovascular prevention. The year in cardiology 2019.
Ray KK; Laufs U; Cosentino F; Lobo MD; Landmesser U
Journal article: REVISTA ROMANA DE CARDIOLOGIE. 2020;30(1):20-29
The year in cardiology: cardiovascular prevention /The year in cardiology 2019
Ray KK; Laufs U; Cosentino F; Lobo M; Landmesser U
Article: EUROPEAN HEART JOURNAL. 2020;41(11):1157-1163
The year in cardiology: cardiovascular prevention The year in cardiology 2019
Ray KK; Laufs U; Cosentino F; Lobo MD; Landmesser U
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2020;22(2):196-213
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure
Seferovic PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferovic J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Article: ECANCERMEDICALSCIENCE. 2020;14:998
Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention
Walker J; Cattaneo M; Badimon L; Agnelli G; Chan AT; Lanas A; Rocca B; Rothwell P; Patrignani P; Langley R; Vilahur G; Cosentino F
Journal article: EUROPEAN HEART JOURNAL. 2020;41(2):255-323
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Cosentino F; Grant PJ; Aboyans V; Bailey CJ; Ceriello A; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TB; Huikuri HV; Johansson I; Juni P; Lettino M; Marx N; Mellbin LG; Ostgren CJ; Rocca B; Roffi M; Sattar N; Seferovic PM; Sousa-Uva M; Valensi P; Wheeler DC; Piepoli MF; Birkeland KI; Adamopoulos S; Ajjan R; Avogaro A; Baigent C; Brodmann M; Bueno H; Ceconi C; Chioncel O; Coats A; Collet J-P; Collins P; Cosyns B; Di Mario C; Fisher M; Fitzsimons D; Halvorsen S; Hansen D; Hoes A; Holt RIG; Home P; Katus HA; Khunti K; Komajda M; Lambrinou E; Landmesser U; Lewis BS; Linde C; Lorusso R; Mach F; Mueller C; Neumann F-J; Persson F; Petersen SE; Petronio AS; Richter DJ; Rosano GMC; Rossing P; Ryden L; Shlyakhto E; Simpson IA; Touyz RM; Wijns W; Wilhelm M; Williams B
Article: EUROPEAN HEART JOURNAL. 2020;41(2):255-323
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Cosentino F; Grant PJ; Aboyans V; Bailey CJ; Ceriello A; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TB; Huikuri HV; Johansson I; Jüni P; Lettino M; Marx N; Mellbin LG; Östgren CJ; Rocca B; Roffi M; Sattar N; Seferović PM; Sousa-Uva M; Valensi P; Wheeler DC; ESC Scientific Document Group
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2020;27(2):168-176
Physical activity may drive healthy microvascular ageing via downregulation of p66^Shc
Streese L; Khan AW; Deiseroth A; Hussain S; Suades R; Tiaden A; Kyburz D; Hanssen H; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2019;40(34):2907-2919
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable
Cosentino F; Ceriello A; Baeres F; Fioretto P; Garber A; Stough WG; George JT; Grant PJ; Khunti K; Langkilde AM; Plutz J; Ryden L; Scheen A; Standl E; Tuomilehto J; Zannad F
Article: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2019;21(C):C37-C39
The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge
Johansson I; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2019;40(4):336-344
The year in cardiology 2018: prevention
Reiner Z; Laufs U; Cosentino F; Landmesser U
Article: EUROPEAN HEART JOURNAL. 2019;40(4):383-391
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66^Shc transcription and vascular oxidative stress in obesity
Costantino S; Paneni F; Virdis A; Hussain S; Mohammed SA; Capretti G; Akhmedov A; Dalgaard K; Chiandotto S; Pospisilik JA; Jenuwein T; Giorgio M; Volpe M; Taddei S; Luscher TF; Cosentino F
Article: AMERICAN HEART JOURNAL. 2018;206:11-23
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Cannon CP; Mcguire DK; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2018;268:179-186
Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66^Shc
Costantino S; Paneni F; Mitchell K; Mohammed SA; Hussain S; Gkolfos C; Berrino L; Volpe M; Schwarzwald C; Luescher TF; Cosentino F
Journal article: EUROPEAN HEART JOURNAL. 2018;39(suppl_1):ehy565.1099
1099Optimizing patient selection in heart failure trials: the role of NT-proBNP
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano G; Dahlstrom U; Lund LH
Journal article: EUROPEAN HEART JOURNAL. 2018;39(suppl_1):ehy566.5210
5210AP-1 transcription factor JunD protects against cardiac microRNA derangement in diabetes
Suades R; Hussein S; Khan AW; Cosentino F
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2018;20(5):853-872
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
Seferovic PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschoepe C; Hoes AW; Seferovic JP; Logue J; McDonagh T; Riley JP; Milinkovic I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV
Article: CURRENT OPINION IN PHARMACOLOGY. 2018;39:86-98
Glucose-lowering treatment in cardiovascular and peripheral artery disease
Suades R; Cosentino F; Badimon L
Article: JACC-HEART FAILURE. 2018;6(3):246-256
Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlstrom U; Lund LH
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2018;25(4):377-387
The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up
Komajda M; Kerneis M; Tavazzi L; Balanescu S; Cosentino F; Cremonesi A; Ferrari R; Kownator S; Szwed H; Mintale I; Olivari Z; Rittger H; Shlyakhto EV; Slapikas R; Steg PG; Valgimigli M; Van Belle E; Tsioufis K; Majda W; Laroche C; Maggioni AP
Article: EUROPEAN HEART JOURNAL. 2018;39(5):345-353
The year in cardiology 2017: prevention
Nordestgaard BG; Cosentino F; Landmesser U; Laufs U
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2018;15(1):14-23
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes
Savonitto S; Morici N; Nozza A; Cosentino F; Filardi PP; Murena E; Morocutti G; Ferri M; Cavallini C; Eijkemans MJC; Stahli BE; Schrieks IC; Toyama T; Heerspink HJL; Malmberg K; Schwartz GG; Lincoff AM; Ryden L; Tardif JC; Grobbee DE
Article: DIABETES. 2017;66(9):2472-2482
Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA_1c Levels
Costantino S; Paneni F; Battista R; Castello L; Capretti G; Chiandotto S; Tanese L; Russo G; Pitocco D; Lanza GA; Volpe M; Luscher TF; Cosentino F
Article: AMERICAN JOURNAL OF MEDICINE. 2017;130(9):1068-1075
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome
Morici N; Savonitto S; Ponticelli C; Schrieks IC; Nozza A; Cosentino F; Stahli BE; Filardi PP; Schwartz GG; Mellbin L; Lincoff AM; Tardif J-C; Grobbee DE
Journal article: EUROPEAN HEART JOURNAL. 2017;38(suppl_1):ehx504.p4478
P4478Cardiac specific overexpression of activated protein-1 transcription factor JunD protects against oxidative stress and left ventricular dysfunction in the diabetic heart
Hussain S; Akhmedov A; Mohammad SA; Gkolfos C; Costantino S; Paneni F; Caidahl K; Cosentino F
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2017;24(3_suppl):52-60
Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor
Norhammar A; Mellbin L; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2016;37(22):1733-1737
Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells
Paneni F; Costantino S; Kraenkel N; Cosentino F; Luscher TF
Article: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2016;18(C):C2-C12
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Ferrari R; Aguiar C; Alegria E; Bonadonna RC; Cosentino F; Elisaf M; Farnier M; Ferrieres J; Filardi PP; Hancu N; Kayikcioglu M; Silva AME; Millan J; Reiner Z; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Luis Zamorano J; Catapano AL
Article: EUROPEAN HEART JOURNAL. 2016;37(6):572-576
MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart
Costantino S; Paneni F; Luescher TF; Cosentino F
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2016;203:702-707
Pin1 inhibitor Juglone prevents diabetic vascular dysfunction
Costantino S; Paneni F; Luescher TF; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2016;37(2):152-160
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT)
Komajda M; Weidinger F; Kerneis M; Cosentino F; Cremonesi A; Ferrari R; Kownator S; Steg PG; Tavazzi L; Valgimigli M; Szwed H; Majda W; Olivari Z; Van Belle E; Shlyakhto EV; Mintale I; Slapikas R; Rittger H; Mendes M; Tsioufis C; Balanescu S; Laroche C; Maggioni AP
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2015;199:415-423
Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction
Savarese G; Edner M; Dahlstrom U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
Article: CARDIOVASCULAR DIAGNOSIS AND THERAPY. 2015;5(5):403-406
Hyperglycemia: a bad signature on the vascular system
Costantino S; Paneni F; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2015;36(31):2097-2109
Healthy lifestyle interventions to combat noncommunicable disease-a novel nonhierarchical connectivity model for key stakeholders: a policy statement from the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Medicine
Arena R; Guazzi M; Lianov L; Whitsel L; Berra K; Lavie CJ; Kaminsky L; Williams M; Hivert M-F; Franklin NC; Myers J; Dengel D; Lloyd-Jones DM; Pinto FJ; Cosentino F; Halle M; Gielen S; Dendale P; Niebauer J; Pelliccia A; Giannuzzi P; Corra U; Piepoli MF; Guthrie G; Shurney D
Article: MAYO CLINIC PROCEEDINGS. 2015;90(8):1082-1103
Healthy Lifestyle Interventions to Combat Noncommunicable Disease-A Novel Nonhierarchical Connectivity Model for Key Stakeholders: A Policy Statement From the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Medicine
Arena R; Guazzi M; Lianov L; Whitsel L; Berra K; Lavie CJ; Kaminsky L; Williams M; Hivert M-F; Franklin NC; Myers J; Dengel D; Lloyd-Jones DM; Pinto FJ; Cosentino F; Halle M; Gielen S; Dendale P; Niebauer J; Pelliccia A; Giannuzzi P; Corra U; Piepoli MF; Guthrie G; Shurney D
Article: CURRENT PHARMACEUTICAL BIOTECHNOLOGY. 2015;16(6):531-543
Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Costantino S; Paneni F; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2015;36(13):817-828
Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes
Paneni F; Costantino S; Castello L; Battista R; Capretti G; Chiandotto S; D'Amario D; Scavone G; Villano A; Rustighi A; Crea F; Pitocco D; Lanza G; Volpe M; Del Sal G; Luescher TF; Cosentino F
Article: CIRCULATION-GENOMIC AND PRECISION MEDICINE. 2015;8(1):150-158
Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus
Paneni F; Costantino S; Battista R; Castello L; Capretti G; Chiandotto S; Scavone G; Villano A; Pitocco D; Lanza G; Volpe M; Luescher TF; Cosentino F
Article: ATHEROSCLEROSIS. 2014;236(2):426-429
p66^Shc-induced redox changes drive endothelial insulin resistance
Paneni F; Costantino S; Cosentino F
Article: CURRENT ATHEROSCLEROSIS REPORTS. 2014;16(7):419
Insulin Resistance, Diabetes, and Cardiovascular Risk
Paneni F; Costantino S; Cosentino F
Article: NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. 2014;24(6):577-584
The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint
Frontoni S; Solini A; Fioretto P; Natali A; Zuccala A; Cosentino F; Penno G
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2014;11(3):133-173
ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary
Ryden L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Sousa M; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Luis Zamorano J; Luis Zamorano J; Achenbach S; Baumgartner H; Bax JJ; Bueno H; Dean V; Deaton C; Erol C; Fagard R; Ferrari R; Hasdai D; Hoes AW; Kirchhof P; Knuuti J; Kolh P; Lancellotti P; Linhart A; Nihoyannopoulos P; Piepoli MF; Ponikowski P; Sirnes PA; Luis Tamargo J; Tendera M; Torbicki A; Wijns W; Windecker S; De Backer G; Sirnes PA; Alegria Ezquerra E; Avogaro A; Badimon L; Baranova E; Baumgartner H; Betteridge J; Ceriello A; Fagard R; Funck-Brentano C; Gulba DC; Hasdai D; Hoes AW; Kjekshus JK; Knuuti J; Kolh P; Lev E; Mueller C; Neyses L; Nilsson PM; Perk J; Ponikowski P; Reiner Z; Sattar N; Schaechinger V; Scheen A; Schirmer H; Stromberg A; Sudzhaeva S; Luis Tamargo J; Viigimaa M; Vlachopoulos C; Xuereb RG
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2014;311(15):1515-1525
Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial
Lincoff AM; Tardif J-C; Schwartz GG; Nicholls SJ; Ryden L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE
Article: EUROPEAN HEART JOURNAL. 2013;34(46):3557-3562
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting
Angeloni E; Paneni F; Landmesser U; Benedetto U; Melina G; Luescher TF; Volpe M; Sinatra R; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2013;34(39):3035-3087
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Ryden L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Zamorano JL
Article: DIABETES. 2013;62(6):1800-1807
SIRT1, p66^Shc, and Set7/9 in Vascular Hyperglycemic Memory
Paneni F; Volpe M; Luescher TF; Cosentino F
Article: CIRCULATION. 2013;127(11):1229-21
Deletion of the Activated Protein-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction
Paneni F; Osto E; Costantino S; Mateescu B; Briand S; Coppolino G; Perna E; Mocharla P; Akhmedov A; Kubant R; Rohrer L; Malinski T; Camici GG; Matter CM; Mechta-Grigoriou F; Volpe M; Luescher TF; Cosentino F
Article: EUROPEAN HEART JOURNAL. 2013;34(2):96-103
Deletion of the ageing gene p66^Shc reduces early stroke size following ischaemia/reperfusion brain injury
Spescha RD; Shi Y; Wegener S; Keller S; Weber B; Wyss MM; Lauinger N; Tabatabai G; Paneni F; Cosentino F; Hock C; Weller M; Nitsch RM; Luescher TF; Camici GG
Article: POLISH HEART JOURNAL-KARDIOLOGIA POLSKA. 2013;71:S319-S394
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Ryden L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Zamorano JL
Article: CURRENT VASCULAR PHARMACOLOGY. 2012;10(6):697-699
p66^Shc as the Engine of Vascular Aging
Paneni F; Cosentino F
Article: CIRCULATION RESEARCH. 2012;111(3):278-289
Gene Silencing of the Mitochondrial Adaptor p66^Shc Suppresses Vascular Hyperglycemic Memory in Diabetes
Paneni F; Mocharla P; Akhmedov A; Costantino S; Osto E; Volpe M; Luescher TF; Cosentino F
Article: JOURNAL OF HYPERTENSION. 2012;30(7):1399-1405
Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study
Ghiadoni L; Faita F; Salvetti M; Cordiano C; Biggi A; Puato M; Di Monaco A; De Siati L; Volpe M; Ambrosio G; Gemignani V; Muiesan ML; Taddei S; Lanza GA; Cosentino F
Journal article: TURK KARDIYOLOJI DERNEGI ARSIVI. 2012;40:5-60
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases
Tendera M; Aboyans V; Bartelink M-L; Baumgartner I; Clement D; Collet J-P; Cremonesi A; De Carlo M; Erbel R; Fowkes FGR; Heras M; Kownator S; Minar E; Ostergren J; Poldermans D; Riambau V; Roffi M; Rother J; Sievert H; van Sambeek M; Zeller T; Bax J; Auricchio A; Baumgartner H; Ceconi C; Dean V; Deaton C; Fagard R; Funck-Brentano C; Hasdai D; Hoes A; Knuuti J; Kolh P; McDonagh T; Moulin C; Poldermans D; Popescu B; Reiner Z; Sechtem U; Sirnes PA; Torbicki A; Vahanian A; Windecker S; Kolh P; Torbicki A; Agewall S; Blinc A; Bulvas M; Cosentino F; De Backer T; Gottsater A; Gulba D; Guzik TJ; Jonsson B; Kesmarky G; Kitsiou A; Kuczmik W; Larsen ML; Madaric J; Mas J-L; McMurray JJV; Micari A; Mosseri M; Muller C; Naylor R; Norrving B; Oto O; Pasierski T; Plouin P-F; Ribichini F; Ricco J-B; Ruilope L; Schmid J-P; Schwehr U; Sol BGM; Sprynger M; Tiefenbacher C; Tsioufis C; Van Damme H
Article: ATHEROSCLEROSIS. 2012;220(1):282-286
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease
Franzeck FC; Hof D; Spescha RD; Hasun M; Akhmedov A; Steffel J; Shi Y; Cosentino F; Tanner FC; von Eckardstein A; Maier W; Luescher TF; Wyss CA; Camici GG
Article: EUROPEAN HEART JOURNAL. 2011;32(22):2851-2906
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)
Tendera M; Aboyans V; Bartelink M-L; Baumgartner I; Clement D; Collet J-P; Cremonesi A; De Carlo M; Erbel R; Fowkes FGR; Heras M; Kownator S; Minar E; Ostergren J; Poldermans D; Riambau V; Roffi M; Roether J; Sievert H; van Sambeek M; Zeller T; Bax J; Auricchio A; Baumgartner H; Ceconi C; Dean V; Deaton C; Fagard R; Funck-Brentano C; Hasdai D; Hoes A; Knuuti J; Kolh P; McDonagh T; Moulin C; Poldermans D; Popescu B; Reiner Z; Sechtem U; Sirnes PA; Torbicki A; Vahanian A; Windecker S; Agewall S; Blinc A; Bulvas M; Cosentino F; De Backer T; Gottsater A; Gulba D; Guzik TJ; Jonsson B; Kesmarky G; Kitsiou A; Kuczmik W; Larsen ML; Madaric J; Mas J-L; McMurray JJV; Micari A; Mosseri M; Muller C; Naylor R; Norrving B; Oto O; Pasierski T; Plouin P-F; Ribichini F; Ricco J-B; Ruilop L; Schmid J-P; Schwehr U; Sol BGM; Sprynger M; Tiefenbacher C; Tsioufis C; Van Damme H
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2011;31(9):2090-2097
Oxidized Low-Density Lipoprotein Activates p66^Shc via Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Protein Kinase C-β, and c-Jun N-Terminal Kinase Kinase in Human Endothelial Cells
Shi Y; Cosentino F; Camici GG; Akhmedov A; Vanhoutte PM; Tanner FC; Luescher TF
Article: CURRENT HYPERTENSION REPORTS. 2011;13(4):318-324
Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade
Volpe M; Cosentino F; Tocci G; Palano F; Paneni F
Article: HIGH BLOOD PRESSURE AND CARDIOVASCULAR PREVENTION. 2011;18(2):43-51
Prevalence of 'Borderline' Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy Results of the BORDERLINE Study
Tocci G; Ferrucci A; Passerini J; Averna M; Bellotti P; Bruno G; Cosentino F; Crepaldi G; Giannattasio C; Modena MG; Nati G; Tiengo A; Trimarco B; Vanuzzo D; Volpe M
Article: STROKE. 2009;40(1):306-308
Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects A Study With Technetium-99m-Ethyl Cysteinate Dimer Single Photon Emission Computed Tomography
Cosentino F; Battista R; Scuteri A; De Sensi F; De Siati L; Di Russo C; Camici GG; Volpe M
Article: CIRCULATION. 2008;118(21):2174-2182
Inhibition of Protein Kinase Cβ Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages
Osto E; Kouroedov A; Mocharla P; Akhmedov A; Besler C; Rohrer L; von Eckardstein A; Iliceto S; Volpe M; Luescher TF; Cosentino F
Article: CIRCULATION. 2008;118(20):2073-2080
c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress
Osto E; Matter CM; Kouroedov A; Malinski T; Bachschmid M; Camici GG; Kilic U; Stallmach T; Boren J; Iliceto S; Luescher TF; Cosentino F
Article: HIGH BLOOD PRESSURE AND CARDIOVASCULAR PREVENTION. 2008;15(2):91-104
Highlights from International Congress : The XI Forum on the Renin-Angiotensin System, Capri, Italy, 11-12 April, 2008.
Azizi M; Borghi C; Coca A; Cosentino F; Crea F; Del Prato S; Lembo G; Mancia G; Modena MG; Rubattu S; Pontremoli R; Ruilope LM; Savoia C; Sciarretta S; Scuteri A; Steckelings UM; Strazzullo P; Trimarco B; Virdis A; Waeber B; Volpe M
Article: HEART. 2008;94(4):487-492
Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia
Cosentino F; Huerlimann D; Gatti CD; Chenevard R; Blau N; Alp NJ; Channon KM; Eto M; Lerch P; Enseleit F; Ruschitzka F; Volpe M; Luescher TF; Noll G
Article: CLINICAL AND EXPERIMENTAL HYPERTENSION. 2008;30(7):616-627
Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells:: Effects of ACE inhibition and AT₁ receptor antagonism
Gatti CD; Osto E; Kouroedov A; Eto M; Shaw S; Volpe M; Luescher TF; Cosentino F
Article: REVISTA ESPANOLA DE CARDIOLOGIA. 2007;60(5):1e-64e
[Guidelines on diabetes, pre-diabetes, and cardiovascular diseases].
Grupo de Trabajo sobre Diabetes y Enfermedades Car; Rydén L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jönsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(12):5217-5222
Genetic deletion of p66^Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress
Camici GG; Schiavoni M; Francia P; Bachschmid M; Martin-Padura I; Hersberger M; Tanner FC; Pelicci P; Volpe M; Anversa P; Luescher TF; Cosentino F
Article: AMERICAN JOURNAL OF HYPERTENSION. 2006;19(12):1213-1216
Nitric oxide release is impaired in hypertensive individuals with familial history of stroke
Cosentino F; Francia P; Musumeci B; De Siati L; Rao MA; De Luca N; Balla C; De Sensi F; Volpe M
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2006;47(5):663-667
Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells
Eto M; Rathgeb L; Cosentino F; Kozai T; Luescher TF
Article: CIRCULATION. 2005;112(9):1316-1322
Glycogen synthase kinase-3 mediates endothelial cell activation by tumor necrosis factor-α
Eto M; Kouroedov A; Cosentino F; Lüscher TF
Article: AMERICAN JOURNAL OF HYPERTENSION. 2005;18(4):493-499
Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists
Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
Article: CURRENT HYPERTENSION REPORTS. 2005;7(1):68-71
Hypertension, stroke, and endothelium
Cosentino F; Volpe M
Article: CIRCULATION. 2003;107(7):1017-1023
High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells - Role of protein kinase C and reactive oxygen species
Cosentino F; Eto M; De Paolis P; van der Loo B; Bachschmid M; Ullrich V; Kouroedov A; Gatti CD; Joch H; Volpe M; Lüscher TF
Article: CIRCULATION. 2002;105(15):1756-1759
Statin prevents tissue factor expression in human endothelial cells -: Role of Rho/Rho-kinase and Akt pathways
Eto M; Kozai T; Cosentino F; Joch H; Lüscher TF
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2001;21(4):496-502
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice
Cosentino F; Barker JE; Brand MP; Heales SJ; Werner ER; Tippins JR; West N; Channon KM; Volpe M; Lüscher TF
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2000;36(3):316-320
Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries
Altwegg LA; d'Uscio LV; Barandier C; Cosentino F; Yang ZH; Lüscher TF
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2000;35(2):173-178
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease
Maier W; Cosentino F; Lütolf RB; Fleisch M; Seiler C; Hess OM; Meier B; Lüscher TF
Article: MINERVA CARDIOANGIOLOGICA. 1999;47(11):376-377
Heterogeneity of endothelial function.
Cosentino F
Article: JOURNAL OF HYPERTENSION. 1998;16(5):609-615
Alterations to the nitric oxide pathway in the spontaneously hypertensive rat
Nava E; Farré AL; Moreno C; Casado S; Moreau P; Cosentino F; Lüscher TF
Article: JOURNAL OF HYPERTENSION. 1998;16(2):151-156
Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats
Russo R; Vecchione C; Cosentino F; Natale A; Mele AF; Muscolo M; Savoia C; Ganten D; Rubattu S; Volpe M
Article: CIRCULATION. 1998;97(1):108-112
Atherosclerosis and the two faces of endothelial nitric oxide synthase
Wever RMF; Lüscher TF; Cosentino F; Rabelink TJ
Article: JOURNAL OF CLINICAL INVESTIGATION. 1997;99(1):41-46
Tetrahydrobiopterin restores endothelial function in hypercholesterolemia
Stroes E; Kastelein J; Cosentino F; Erkelens W; Wever R; Koomans H; Luscher T; Rabelink T
Article: JOURNAL OF CLINICAL INVESTIGATION. 1996;98(4):899-905
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
Tschudi MR; Barton M; Bersinger NA; Moreau P; Cosentino F; Noll G; Malinski T; Luscher TF
Article: NEUROSURGERY. 1995;36(1):58-63
Glossopharyngeal neuralgia with cardiac syncope.
Ferrante L; Artico M; Nardacci B; Fraioli B; Cosentino F; Fortuna A
Article: CIRCULATION. 1995;91(1):139-144
TETRAHYDROBIOPTERIN AND DYSFUNCTION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IN CORONARY-ARTERIES
COSENTINO F; KATUSIC ZS
Journal article: STROKE. 1994;25(4):904-908
DOES ENDOTHELIN-1 PLAY A ROLE IN THE PATHOGENESIS OF CEREBRAL VASOSPASM
COSENTINO F; KATUSIC ZS
Journal article: STROKE. 1993;24(3):392-399
SUBARACHNOID HEMORRHAGE AND ENDOTHELIAL L-ARGININE PATHWAY IN SMALL BRAIN-STEM ARTERIES IN DOGS
KATUSIC ZS; MILDE JH; COSENTINO F; MITROVIC BS
Journal article: JOURNAL OF HYPERTENSION, SUPPLEMENT. 1991;9(6):S202-S203
REGRESSION OF STRUCTURAL VASCULAR CHANGES AFTER CHRONIC TREATMENT IN HYPERTENSIVES
NOVO S; ABRIGNANI MG; LIQUORI M; CORDA M; PINTO A; COSENTINO F; STRANO A
Show more

All other publications

Review: EUROPEAN HEART JOURNAL. 2025;:ehaf164
Delivering a European Union cardiovascular health plan: from building momentum to political action
Fitzsimons D; Cosentino F; Linde C; Price S; Luscher TF; Weidinger F
Editorial comment: EUROPEAN HEART JOURNAL. 2025;46(12):1109-1111
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
Verma S; Cosentino F; Kosiborod MN
Editorial comment: CARDIOVASCULAR DIABETOLOGY. 2025;24(1):68
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
Barnard-Kelly K; Battelino T; Brosius FC; Ceriello A; Cosentino F; Gavin III JR; Giorgino F; Green J; Ji L; Kellerer M; Koob S; Kosiborod M; Lalic N; Marx N; Nedungadi P; Parkin CG; Rodbard HW; Roetzer RD; Ryden L; Sheu WH-H; Standl E; Jeppesen BT; Topsever P; Vandvik PO; Wanner C; Schnell O
Letter: DIABETES OBESITY & METABOLISM. 2024;26(8):3478-3481
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
Odutayo A; Cosentino F; Pratley RE; Dagogo-Jack S; McGuire DK; Frederich R; Fu W; Cannon CP; Cherney DZI
Editorial comment: EUROPEAN HEART JOURNAL. 2024;45(14):1205-1208
The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders
Cosentino F; Cannon CP; Marx N
Review: DIABETES-METABOLISM RESEARCH AND REVIEWS. 2024;40(3):e3755
Cardio-renal-metabolic disease in primary care setting
Ibrahim M; Ba-Essa EM; Baker J; Cahn A; Ceriello A; Cosentino F; Davies MJ; Eckel RH; Van Gaal L; Gaede P; Handelsman Y; Klein S; Leslie RD; Pozzilli P; Del Prato S; Prattichizzo F; Schnell O; Seferovic PM; Standl E; Thomas A; Tuomilehto J; Valensi P; Umpierrez GE
Review: AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 2024;326(3):H670-H688
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma S; Pandey A; Pandey AK; Butler J; Lee JS; Teoh H; Mazer CD; Kosiborod MN; Cosentino F; Anker SD; Connelly KA; Bhatt DL
Editorial comment: CARDIOVASCULAR RESEARCH. 2024;119(18):2771-2773
Cardiometabolic disease: linking pathogenic mechanisms to therapeutic opportunities
Chavakis T; Cosentino F; Schmidt AM
Review: CARDIOVASCULAR RESEARCH. 2024;119(18):2858-2874
Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
Terenzi DC; Bakbak E; Teoh H; Krishnaraj A; Puar P; Rotstein OD; Cosentino F; Goldenberg RM; Verma S; Hess DA
Review: POLISH HEART JOURNAL-KARDIOLOGIA POLSKA. 2024;82(10):935-940
Stronger together: The impact of Joint Advocacy efforts for European Union and National Cardiovascular Health Plans
Szymanski P; Cosentino F; Fitzsimons D; Traykov V; Aboyans V; Bueno H; Witkowski A; Gil R; Mitkowski P
Corrigendum: DIABETES THERAPY. 2024;15(1):297-299
New-Onset Diabetes Mellitus in COVID-19: A Scoping Review (sept, 10.1007/s13300-023-01465-7, 202#)
Pantea Stoian A; Bica I-C; Salmen T; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kalra S; Kapoor N; Kempler P; Lessan N; Lotufo P; Mikhailidis DP; Nibali L; Papanas N; Powell-Wiley T; Rizvi AA; Sahebkar A; Santos RD; Toth PP; Viswanathan V; Rizzo M
Review: DIABETES THERAPY. 2024;15(1):33-60
New-Onset Diabetes Mellitus in COVID-19: A Scoping Review
Stoian AP; Bica I-C; Salmen T; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kalra S; Kapoor N; Kempler P; Lessan N; Lotufo P; Mikhaildiis DP; Nibali L; Papanas N; Powell-Wiley T; Rizvi AA; Sahebkar A; Santos RD; Toth PP; Viswanathan V; Rizzo M
Review: EUROPEAN HEART JOURNAL. 2023;44(39):4141-4156
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Cosentino F; Verma S; Ambery P; Treppendahl MB; van Eickels M; Anker SD; Cecchini M; Fioretto P; Groop P-H; Hess D; Khunti K; Lam CSP; Richard-Lordereau I; Lund LH; McGreavy P; Newsome PN; Sattar N; Solomon S; Weidinger F; Zannad F; Zeiher A
Editorial comment: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):277
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
Ceriello A; Rodbard HW; Battelino T; Brosius F; Cosentino F; Green J; Ji L; Kellerer M; Koob S; Kosiborod M; Lalic N; Marx N; Nedungadi TP; Parkin CG; Ryden L; Sheu WH-H; Standl E; Vandvik PO; Schnell O
Review: EUROPEAN HEART JOURNAL. 2023;44(37):3640-3651
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Pandey AK; Bhatt DL; Pandey A; Marx N; Cosentino F; Pandey A; Verma S
Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S349
Effect of ertugliflozin on body weight and HbA_1cby baseline BMI: observations from VERTIS CV
Cosentino F; Cherney DZI; Dagogo-Jack S; Pratley RE; Cater N; Maldonado M; Xing A; Cannon CP
Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S142
268 Endothelial-specific deletion of lysine methyltransferase Set7 protects mice from obesity and insulin resistance-related endothelial dysfunction
Sanchez-Ceinos J; Dottling P; Jakobsson M; Vegvari A; Cosentino F
Editorial comment: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25(7):936-955
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
Anker SD; Usman MS; Anker MS; Butler J; Boehm M; Abraham WT; Adamo M; Chopra VK; Cicoira M; Cosentino F; Filippatos G; Jankowska EA; Lund LH; Moura B; Mullens W; Pieske B; Ponikowski P; Gonzalez-Juanatey JR; Rakisheva A; Savarese G; Seferovic P; Teerlink JR; Tschoepe C; Volterrani M; von Haehling S; Zhang J; Zhang Y; Bauersachs J; Landmesser U; Zieroth S; Tsioufis K; Bayes-Genis A; Chioncel O; Andreotti F; Agabiti-Rosei E; Merino JL; Metra M; Coats AJS; Rosano GMC
Review: FRONTIERS IN ENDOCRINOLOGY. 2023;14:1129793
Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement
Rosta L; Menyhart A; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kalra S; Kapoor N; Lessan N; Lotufo P; Papanas N; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Kempler P; Rizzo M
Letter: DIABETES OBESITY & METABOLISM. 2023;25(5):1398-1402
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease
Kim JM; Bhatt DL; Dagogo-Jack S; Cherney DZI; Cosentino F; McGuire DK; Pratley RE; Liu C-C; Cater NB; Frederich R; Mancuso JP; Cannon CP
Review: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES. 2023;131(05):260-267
Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel
Popovic DS; Papanas N; Koufakis T; Kotsa K; Mahmeed WA; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kalra S; Kempler P; Kapoor N; Lessan N; Lotufo P; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Corrigendum: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2023;9(3):293
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis (Vol 9, pg 10, 2023)
Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
Conference publication: DIABETES RESEARCH AND CLINICAL PRACTICE. 2023;197:110329
Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV
Cosentino F; Dagogo-Jack S; Frederich R; Cannon CP; Cherney DZI; Mancuso JP; Wynant W; Liu J; Cater NB; Pratley RE
Editorial comment: EUROPEAN HEART JOURNAL. 2023;44(6):448-451
The year in cardiovascular medicine 2022: the top 10 papers in diabetes and metabolic disorders
Cosentino F; Marx N; Verma S
Review: METABOLITES. 2022;13(1):40
Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence
Mainas G; Nibali L; Ide M; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kalra S; Kapoor N; Kempler P; Lessan N; Lotufo P; Papanas N; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Corrigendum: EUROPEAN HEART JOURNAL. 2022;43(41):4391
Erratum to: Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Review: DIABETES THERAPY. 2022;13(10):1723-1736
The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact
Kapoor N; Kalra S; Al Mahmeed W; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh S-Y; Janez A; Kempler P; Lessan N; Lotufo P; Papanas N; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Conference publication: EUROPEAN HEART JOURNAL. 2022;43:962
Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial
Pandey A; Kolkailah AA; Cosentino F; Cannon CP; Frederich R; Cherney DZI; Dagogo-Jack S; Pratley RE; Cater NB; Gantz I; Mancuso JP; McGuire DK
Review: HEART FAILURE CLINICS. 2022;18(4):551-559
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Ferrannini G; Savarese G; Cosentino F
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S133
Efficacy of ertugliflozin (ERTU) on hospitalisation for heart failure (HHF) across the spectrum of pre-trial ejection fraction (EF): post hoc analyses of VERTIS CV
Pandey A; Kolkailah AA; Cosentino F; Cannon CP; Frederich R; Cherney DZI; Dagogo-Jack S; Pratley RE; Cater NB; Gantz I; Mancuso JP; McGuire DK
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S318-S319
Effects of ertugliflozin on uric acid and gout-related outcomes: post hoc analyses from VERTIS CV
Sridhar VS; Cosentino F; Dagogo-Jack S; Pratley R; Frederich R; Essex MN; Maldonado M; Liu C-C; Mancuso JP; Cherney DZI
Letter: CIRCULATION. 2022;146(8):652-654
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
Cosentino F; Cannon CP; Frederich R; Cherney DZI; Dagogo-Jack S; Pratley RE; Mancuso JP; Maldonado M; Cater NB; Wang S; McGuire DK
Review: EUROPEAN HEART JOURNAL. 2022;43(31):2931-2945
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Editorial comment: EUROPEAN HEART JOURNAL. 2022;43(31):2994-2996
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure
Verma S; Dhingra NK; Pandey AK; Cosentino F
Review: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(9):1352-1360
Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
Fontes-Carvalho R; Santos-Ferreira D; Raz I; Marx N; Ruschitzka F; Cosentino F
Editorial comment: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2022;15(7):795-797
Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes
Rizzo M; Cosentino F; Mantzoros C
Letter: DIABETOLOGIA. 2022;65(5):908-911
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]
Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP
Review: EUROPEAN HEART JOURNAL. 2022;43(6):450-459
Vascular repair and regeneration in cardiometabolic diseases
Hess DA; Verma S; Bhatt D; Bakbak E; Terenzi DC; Puar P; Cosentino F
Editorial comment: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2021;28(15):e19-e21
High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology
Hansen D; Mellbin L; Cosentino F; De Bacquer D; Grobbee D; Van Ryckeghem L; Standl E; Beulens JWJ
Review: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):218
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello A; Catrinoiu D; Chandramouli C; Cosentino F; Dombrowsky AC; Itzhak B; Lalic NM; Prattichizzo F; Schnell O; Seferovic PM; Valensi P; Standl E
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:2925
Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
Cherney DZI; Segar M; Pandey A; Cannon CP; Cosentino F; Dagogo-Jack S; Pratley RE; Frederich R; Cater NB; Maldonado M; Liu J; Liu C-C; Pong A; McGuire DK
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:1150
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Kerneis M; Cosentino F; Ferrari R; Georges JL; Kosmachova E; Laroche C; Maggioni AP; Rittger H; Steg PG; Szwed H; Tavazzi L; Valgimigli M; Gale CP; Komajda M
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:2649
Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
Segar MW; Pandey A; Cherney DZI; Cannon CP; Cosentino F; Dagogo-Jack S; Pratley RE; Shih WJ; Frederich R; Cater NB; Maldonado M; Liu J; Liu C; Pong A; McGuire DK
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:2650
Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial
Cosentino F; Cannon CP; Cherney DZI; Dagogo-Jack S; Pratley RE; Charbonnel B; Shih WJ; Mancuso JP; Maldonado M; Frederich R; Cater NB; Wang S; McGuire DK
Review: EUROINTERVENTION. 2021;17(8):e618-e630
Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
Johansson I; Dicembrini I; Mannucci E; Cosentino F
Review: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2021;10(18):e019918
Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression
Odutayo A; da Costa BR; Pereira TV; Garg V; Iskander S; Roble F; Lalji R; Hincapie CA; Akingbade A; Rodrigues M; Agarwal A; Lawendy B; Saadat P; Udell JA; Cosentino F; Grant PJ; Verma S; Juni P
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):226
Cardiorenal outcomes with ertugliflozin by baseline glucose-lowering agent: an analysis from VERTIS CV
Charbonnel B; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Shih WJ; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):218-219
Long-term effects of ertugliflozin (ERTU) on liver enzymes and indices in patients with type 2 diabetes: analyses from VERTIS CV
Corbin KD; Dagogo-Jack S; Cannon CP; Charbonnel B; Cherney DZI; Cosentino F; McGuire DK; Shih WJ; Frederich R; Liu J; Pong A; Cater NB; Pratley RE
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):225-226
Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV
Dagogo-Jack S; Pratley RE; Cherney DZI; Charbonnel B; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):30-31
Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
Pratley RE; Cannon CP; Charbonnel B; Cherney DZI; Cosentino F; McGuire DK; Shih WJ; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons IA; Dagogo-Jack S
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):29-30
Cardiorenal outcomes with ertugliflozin by baseline cardiorenal medications: an analysis from VERTIS CV
Cannon CP; Cosentino F; McGuire DK; Charbonnel B; Dagogo-Jack S; Pratley RE; Shih WJ; Maldonado M; Pong A; Gantz I; Frederich R; Mancuso JP; Masiukiewicz U; Cherney DZI
Editorial comment: EUROPEAN JOURNAL OF HEART FAILURE. 2021;23(8):1260-1275
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors
Herrington WG; Savarese G; Haynes R; Marx N; Mellbin L; Lund LH; Dendale P; Seferovic P; Rosano G; Staplin N; Baigent C; Cosentino F
Review: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;177:108870
Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020
Marx N; Ryden L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi TP; Rodbard HW; Vandvik PO; Ji L; Sheu WH-H; Standl E; Schnell O
Corrigendum: ESC HEART FAILURE. 2021;8(3):2363
Corrigendum.
Editorial comment: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(3):e4
SGLT2i: new perspectives in diabetes and kidney disease
Ferrannini G; Cosentino F
Editorial comment: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):75
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Schnell O; Cos X; Cosentino F; Forst T; Giorgino F; Heersprink HJL; Kosiborod M; Wanner C; Standl E
Letter: LANCET DIABETES & ENDOCRINOLOGY. 2021;9(3):139-140
Positioning newer drugs in the management of type 2 diabetes
Marx N; Davies MJ; Grant PJ; Mathieu C; Petrie JR; Cosentino F; Buse JB
Letter: CIRCULATION. 2021;143(6):602-605
Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function Observations From VERTIS CV
Cherney DZI; McGuire DK; Charbonnel B; Cosentino F; Pratley R; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu C-C; Cannon CP
Review: LANCET DIABETES & ENDOCRINOLOGY. 2021;9(1):46-52
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Marx N; Davies MJ; Grant PJ; Mathieu C; Petrie JR; Cosentino F; Buse JB
Review: CARDIOVASCULAR RESEARCH. 2021;117(1):29-42
Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardioloy working Groups on Artherosclerosis and Vascular Biology, Aorta and Perirpheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis
Alexander Y; Osto E; Schmidt-Trucksass A; Shechter M; Trifunovic D; Duncker DJ; Aboyans V; Back M; Badimon L; Cosentino F; De Carlo M; Dorobantu M; Harrison DG; Guzik TJ; Hoefer I; Morris PD; Norata GD; Suades R; Taddei S; Vilahur G; Waltenberger J; Weber C; Wilkinson F; Bochaton-Piallat M-L; Evans PC
Conference publication: CIRCULATION. 2020;142(24):E483
Should Cardiologists Risk-stratify Patients With Atherosclerotic Cardiovascular Disease by Kidney Function? Results From the VERTIS CV Trial Evaluating Efficacy of Ertugliflozin on Cardiovascular and Kidney Outcomes by Baseline Kidney Function
Cherney D; Charbonnel B; Cosentino F; Pratley R; Dagogo-Jack S; Shih WJ; McGuire DK; Frederich R; Maldonado M; Liu J; Pong A; Liu C-C; Cannon CP
Review: ESC HEART FAILURE. 2020;7(6):3438-3451
Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
Savarese G; Schrage B; Cosentino F; Lund LH; Rosano GMC; Seferovic P; Butler J
Editorial comment: EUROPEAN HEART JOURNAL. 2020;41(36):3419-3420
The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns
Savarese G; Cosentino F
Editorial comment: DIABETES TECHNOLOGY & THERAPEUTICS. 2020;22(7):546-552
Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases
Marx N; Ryden L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi P; Rodbard HW; Vandvik PO; Standl E; Schnell O
Corrigendum: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2020;27(8):NP3
CORRIGENDUM: Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry.
Editorial comment: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2020;22(C):C1
Prevention and treatment of venous thromboembolism
Casadei B; Cosentino F
Editorial comment: CARDIOVASCULAR RESEARCH. 2020;116(5):879-881
CardioScape-II: the need tomap cardiovascular funding patterns in Europe
Pries AR; Vardas P; Ballensiefen W; Cosentino F; Dunkel M; Guzik T; Pearson J; Preissner R; Van de Werf F; Wood D
Editorial comment: DIABETES RESEARCH AND CLINICAL PRACTICE. 2020;162:108092
Proceedings of the Guideline Workshop 2019 Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases
Marx N; Ryden L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi P; Rodbard HW; Vandvik PO; Standl E; Schnell O
Review: DIABETES OBESITY & METABOLISM. 2020;22(2):149-157
Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?
Giugliano D; Ceriello A; De Nicola L; Perrone-Filardi P; Cosentino F; Esposito K
Editorial comment: EUROPEAN HEART JOURNAL. 2020;41(2):329-330
Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
Marx N; Grant PJ; Cosentino F
Editorial comment: EUROPEAN HEART JOURNAL. 2019;40(48):3948-3949
Exercise-induced improvement of microvascular phenotype and reprogramming of p66^Shc DNA methylation
Streese L; Suades R; Cosentino F; Hanssen H
Editorial comment: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_SUPPL):5-6
Cardio-diabetology: The new 'sweetheart' in cardiovascular prevention Introduction
Aboyans V; Cosentino F
Editorial comment: CARDIOVASCULAR RESEARCH. 2019;115(13):e147-e150
The environment, epigenetic landscape and cardiovascular risk
Suades R; Cosentino F
Editorial comment: EUROPEAN HEART JOURNAL. 2019;40(39):3215-3217
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD New features and the 'Ten Commandments' of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen
Grant PJ; Cosentino F
Editorial comment: EUROPEAN HEART JOURNAL. 2019;40(34):e11-e13
Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies
Paneni F; Costantino S; Cosentino F
Review: EUROPEAN HEART JOURNAL. 2019;40(21):1720-1727
The future of continuing medical education: the roles of medical professional societies and the health care industry Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology
Bax J; Casadei B; Graham I; Pinto F; Anker S; Badimon L; Merkaly B; Bueno H; Clarke S; Fitzsimons D; Leclerq C; Linde C; Weidinger F; Lettino M; Popescu B; Grobbee D; Haude M; Hindricks G; Ruschitzka F; Achenbach S; Clarke N; Cosentino F; Filippatos G; Kearney P; Kirchhof P; Kristensen SD; Luscher T; Olsson G; Vahanian A; Windecker S; Zamorano J
Editorial comment: CARDIOVASCULAR RESEARCH. 2019;115(3):485-487
Sirtuin 1/soluble guanylyl cyclase: a nitric oxide-independent pathway to rescue ageing-induced vascular dysfunction
Suades R; Cosentino F
Review: EUROPEAN HEART JOURNAL. 2018;39(48):4243-4254
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology
Maack C; Lehrke M; Backs J; Heinzel FR; Hulot J-S; Marx N; Paulus WJ; Rossignol P; Taegtmeyer H; Bauersachs J; Bayes-Genis A; Brutsaert D; Bugger H; Clarke K; Cosentino F; De Keulenaer G; Dei Cas A; Gonzalez A; Huelsmann M; Iaccarino G; Lunde IG; Lyon AR; Pollesello P; Rena G; Riksen NP; Rosano G; Staels B; van Laake LW; Wanner C; Farmakis D; Filippatos G; Ruschitzka F; Seferovic P; de Boer RA; Heymans S
Conference publication: DIABETOLOGIA. 2018;61:S305-S306
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
McGuire DK; Cannon CP; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG
Review: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2018;1864(9):2814-2821
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo M; Nikolic D; Patti AM; Mannina C; Montalto G; McAdams BS; Rizvi AA; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2018;39:1076-1077
AP-1 transcription factor JunD protects against cardiac microRNA derangement in diabetes
Suades R; Hussein S; Khan AW; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2018;39:223
Optimizing patient selection in heart failure trials: the role of NT-proBNP
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano G; Dahlstrom U; Lund LH
Review: ANTIOXIDANTS & REDOX SIGNALING. 2018;29(3):257-274
Epigenetics and Immunometabolism in Diabetes and Aging
Guzik TJ; Cosentino F
Editorial comment: EUROPEAN HEART JOURNAL. 2018;39(25):2387-2389
Diabetes and ischaemic stroke: a deadly association
Fadini GP; Cosentino F
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2018;20:284-285
Optimizing criteria for N-terminal pro-B-type natriuretic peptide for eligibility and enrichment in trials in heart failure with preserved, mid-range and reduced ejection fraction
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano G; Dahlstrom U; Lund LH
Conference publication: EUROPEAN HEART JOURNAL. 2017;38:936-937
Cardiac specific overexpression of activated protein-1 transcription factor JunD protects against oxidative stress and left ventricular dysfunction in the diabetic heart
Hussain S; Akhmedov A; Mohammad SA; Gkolfos C; Costantino S; Paneni F; Caidahl K; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2016;37:1009
Methyltransferase Set7 drives vascular inflammation and endothelial dysfunction in obesity
Paneni F; Costantino S; Virdis A; Volpe M; Luscher TF; Taddei S; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2016;37:843
Targeting miR-218 and mi-R34a protects against maladaptive chromatin remodelling and oxidative stress in the diabetic heart
Costantino S; Paneni F; Mitchell K; Berrino L; Schwarzwald C; Volpe M; Luscher TF; Cosentino F
Conference publication: CARDIOVASCULAR RESEARCH. 2016;111:S43
miR-218 and mi-R34a drive persistent myocardial oxidative stress by targeting chromatin remodelers DNMT3b and SIRT1: new mechanistic insights in diabetic cardiomyopathy
Costantino S; Paneni F; Mitchell K; Berrino L; Schwarzwald C; Volpe M; Luscher TF; Cosentino F
Review: JOURNAL OF PHYSIOLOGY-LONDON. 2016;594(8):2061-2073
Ageing, metabolism and cardiovascular disease
Costantino S; Paneni F; Cosentino F
Review: ATHEROSCLEROSIS SUPPLEMENTS. 2015;19:1-12
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrieres J; Filardi PP; Hancu N; Kayikcioglu M; Mello e Silva A; Millan J; Reiner Z; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Luis Zamorano J; Ferrari R
Conference publication: EUROPEAN HEART JOURNAL. 2015;36:112-113
Chromatin changes by methyltransferase Set7 induce inflammatory adhesion molecules and endothelial dysfunction in small visceral arteries from insulin resistant subjects
Costantino S; Paneni F; Virdis A; Volpe M; Taddei S; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2015;36:22-23
Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction
Savarese G; Edner M; Dahlstrom U; Perrone-Filardi P; Cosentino F; Lund LH
Review: ATHEROSCLEROSIS. 2015;241(2):507-532
The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society
Vlachopoulos C; Xaplanteris P; Aboyans V; Brodmann M; Cifkova R; Cosentino F; De Carlo M; Gallino A; Landmesser U; Laurent S; Lekakis J; Mikhailidis DP; Naka KK; Protogerou AD; Rizzoni D; Schmidt-Trucksaess A; Van Bortel L; Weber T; Yamashina A; Zimlichman R; Boutouyrie P; Cockcroft J; O'Rourke M; Park JB; Schillaci G; Sillesen H; Townsend RR
Conference publication: CARDIOLOGY. 2015;131:18
The Year in Cardiology - The EHJ Perspective - Prevention
Cosentino F
Review: GIORNALE ITALIANO DI CARDIOLOGIA. 2015;16(4):225-231
Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications
Paneni F; Costantino S; Cosentino F
Review: WORLD JOURNAL OF DIABETES. 2015;6(2):326-332
Role of oxidative stress in endothelial insulin resistance
Paneni F; Costantino S; Cosentino F
Book: 2015
Diabetes and Cardiovascular Disease, A Guide to Clinical Management
Paneni F; Cosentino F
Review: CLINICAL SCIENCE. 2015;128(2):69-79
Molecular pathways of arterial aging
Paneni F; Costantino S; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2014;35:857
SIRT1 drives persistent myocardial dysfunction via epigenetic regulation of mitochondrial adaptor p66Shc in the diabetic heart
Costantino S; Paneni F; Mitchell K; Berrino L; Volpe M; Schwarzwald C; Luscher TF; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2014;35:689
Postprandial hyperglycemia but not glycated hemoglobin predicts adverse epigenetic signatures and vascular dysfunction in type 2 diabetic patients with optimal glycemic control
Paneni F; Costantino S; Battista R; Castello L; Chiandotto S; Capretti G; Scavone G; Lanza G; Volpe M; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2014;35:681-682
Methyltransferase Set7 induces NF-kB-dependent vascular inflammation and dysfunction in visceral fat arteries of obese individuals
Costantino S; Paneni F; Virdis A; Volpe M; Taddei S; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2014;35:347
Prolyl-isomerase-1 (Pin1) causes endothelial dysfunction and vascular inflammation in diabetes: a study in mice and humans
Paneni F; Costantino S; Battista R; Castello L; Capretti G; Chiandotto S; Del Sal G; Volpe M; Luscher TF; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2014;35:274
In vivo silencing of mitochondrial adaptor p66Shc gene improves endothelial insulin resistance in obese mice
Costantino S; Paneni F; Cosentino F
Review: CARDIOVASCULAR DIAGNOSIS AND THERAPY. 2014;4(4):324-332
Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes
Paneni F; Costantino S; Cosentino F
Corrigendum: EUROPEAN HEART JOURNAL. 2014;35(27):1824
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (vol 34, pg 3035, 2013)
Ryden L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Zamorano JL
Editorial comment: EUROPEAN HEART JOURNAL. 2014;35(17):1095-1097
Advanced glycation end products and plaque instability: a link beyond diabetes
Paneni F; Cosentino F
Review: EUROPEAN HEART JOURNAL. 2014;35(17):1112-1119
Non-coronary atherosclerosis
Gallino A; Aboyans V; Diehm C; Cosentino F; Stricker H; Falk E; Schouten O; Lekakis J; Amann-Vesti B; Siclari F; Poredos P; Novo S; Brodmann M; Schulte K-L; Vlachopoulos C; De Caterina R; Libby P; Baumgartner I
Conference publication: CIRCULATION. 2013;128(22)
Reprogramming Epigenetic Changes Blunts p66Shc-induced Vascular Dysfunction In Experimental and Human Obesity: Insights for Mechanisms-Based Therapeutic Strategies
Paneni F; Costantino S; Capretti G; Virdis A; Chiandotto S; Rocca B; Luescher T; Taddei S; Volpe M; Cosentino F
Conference publication: CIRCULATION. 2013;128(22)
Epigenetic Signatures of p66Shc Promoter Contribute to Persistent Endothelial Dysfunction in Type 2 Diabetics With Optimal Glycemic Control
Paneni F; Costantino S; Castello L; Battista R; Capretti G; Chiandotto S; Luescher T; Lanza G; Volpe M; Cosentino F
Review: ATHEROSCLEROSIS. 2013;230(2):191-197
Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective
Paneni F; Costantino S; Volpe M; Luescher TF; Cosentino F
Review: EUROPEAN HEART JOURNAL. 2013;34(31):2436-2443
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni F; Beckman JA; Creager MA; Cosentino F
Review: EUROPEAN HEART JOURNAL. 2013;34(31):2444-2452
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman JA; Paneni F; Cosentino F; Creager MA
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:1054
Aging and longevity genes p66shc and junD mediate age-related dysfunction of angiogenic early outgrowth cells: mechanistic insights into vascular repair
Paneni F; Costantino S; Krankel N; Cosentino F; Luscher TF
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:604
Prolyl-isomerase-1 (pin1) mediates hyperglycemia-induced oxidative stress, endothelial function and vascular inflammation: insights in patients with type 2 diabetes
Paneni F; Costantino S; Battista R; Capretti G; Castello L; Chiandotto S; Volpe M; Luscher TF; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:315
Hyperglycemia-induced myocardial oxidative stress and inflammation persist despite optimal glycemic control: role of mitochondrial adaptor p66shc
Costantino S; Paneni F; Berrino L; Volpe M; Luscher TF; Cosentino F
Conference publication: JOURNAL OF VASCULAR RESEARCH. 2013;50:33
EPIGENETIC SIGNATURES INDUCED BY THE ACETYLTRANSFERASE GCN5 MEDIATE OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN DIABETES
Costantino S; Paneni F; Battista R; Capretti G; Castello L; Chiandotto S; Volpe M; Luecher TF; Cosentino F
Editorial comment: CURRENT VASCULAR PHARMACOLOGY. 2012;10(6):677
Proceedings of the Symposium "Cardiovascular Risk and Vascular Disease - from Mechanisms to Treatment"
Cosentino F
Review: ATHEROSCLEROSIS. 2012;224(1):25-36
"In vivo" imaging of atherosclerosis
Gallino A; Stuber M; Crea F; Falk E; Corti R; Lekakis J; Schwitter J; Camici P; Gaemperli O; Di Valentino M; Prior J; Garcia-Garcia HM; Vlachopoulos C; Cosentino F; Windecker S; Pedrazzini G; Conti R; Mach F; De Caterina R; Libby P
Letter: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2012;158(1):158-160
The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study
Paneni F; Cosentino F; Marrara F; Palano F; Capretti G; Gregori M; Tocci G; Testa M; Volpe M
Review: JOURNAL OF CARDIOVASCULAR RISK. 2011;18(6):775-789
Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation
Lekakis J; Abraham P; Balbarini A; Blann A; Boulanger CM; Cockcroft J; Cosentino F; Deanfield J; Gallino A; Ikonomidis I; Kremastinos D; Landmesser U; Protogerou A; Stefanadis C; Tousoulis D; Vassalli G; Vink H; Werner N; Wilkinson I; Vlachopoulos C
Conference publication: CIRCULATION. 2011;124(21)
Insulin Resistant Mice Lacking p66^Shc Gene are Protected Against Endothelial Dysfunction
Paneni F; Capretti G; Di Stasio E; Akhmedov A; Petrucci G; Perna E; Osto E; Luscher TF; Volpe M; Cosentino F
Letter: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2011;151(3):384-385
Is there any memory effect of blood pressure lowering in diabetes?
Paneni F; Cosentino F; Passerini J; Volpe M
Conference publication: EUROPEAN HEART JOURNAL. 2011;32:796
Genetic deletion of the p66Shc adaptor protein protects against age-related cardiac arrhythmias
Francia P; Ricotta A; Uccellini A; Balla C; Adduci C; Carosio S; Barberi L; Musaro' A; Cosentino F; Volpe M
Conference publication: EUROPEAN HEART JOURNAL. 2011;32:521-522
Transient in vivo knockdown of the mammalian adaptor p66Shc blunts the hyperglycaemic memory
Paneni F; Mocharla P; Akhmedov A; Osto E; Volpe M; Luscher TF; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2011;32:361
Deletion of p66Shc gene restores endothelial function in a mouse model of obesity and insulin resistance
Capretti G; Paneni F; Di Stasio E; Petrucci G; Perna E; Francia P; Patrono C; Volpe M; Cosentino F
Review: GERONTOLOGY. 2011;57(2):101-108
Anti-Aging Medicine: Molecular Basis for Endothelial Cell-Targeted Strategies - A Mini-Review
Camici GG; Shi Y; Cosentino F; Francia P; Luescher TF
Conference publication: CIRCULATION. 2010;122(21)
Role of PKCβII/p66^Shc Pathway As A Determinant Of Metabolic Memory In Human Endothelial Cells
Paneni F; Mocharla P; Osto E; Volpe M; Luscher TF; Cosentino F
Conference publication: EUROPEAN HEART JOURNAL. 2010;31:95
oxLDL mediated p66shc activation and ROS production goes through LOX-1receptor-1 and mediated by protein kinase C beta and c-Jun N-terminal kinase in human aortic endothelial cells
Shi Y; Cosentino F; Camici G; Akhmedov A; Vanhoutte P; Tanner F; Luscher T
Review: NEUROLOGICAL SCIENCES. 2010;31(1):1-8
Alzheimer's disease and endothelial dysfunction
Bomboi G; Castello L; Cosentino F; Giubilei F; Orzi F; Volpe M
Review: JOURNAL OF MOLECULAR MEDICINE-JMM. 2009;87(9):885-891
p66^Shc protein, oxidative stress, and cardiovascular complications of diabetes: the missing link
Francia P; Cosentino F; Schiavoni M; Huang Y; Perna E; Camici GG; Luescher TF; Volpe M
Editorial comment: EUROPEAN HEART JOURNAL. 2009;30(11):1301-1304
Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?
Bartnik M; Cosentino F
Review: JOURNAL OF APPLIED PHYSIOLOGY. 2008;105(5):1628-1631
The role of p66^Shc deletion in age-associated arterial dysfunction and disease states
Camici GG; Cosentino F; Tanner FC; Luescher TF
Review: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2008;28(4):622-628
Final common molecular pathways of aging and cardiovascular disease -: Role of the p66^Shc protein
Cosentino F; Francia P; Camici GG; Pelicci PG; Luescher TF
Review: REVISTA PORTUGUESA DE CARDIOLOGIA. 2007;26(11):1213-1274
[Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary].
Rydén L; Standl E; Bartnik MG; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jönsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Grupo de trabalho da European Society of Cardiolog; European Association for the Study of Diabetes
Review: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2007;9(C):C3-C74
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Luis Zamorano J; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; GohIke H; Gonzalez Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Review: CURRENT PHARMACEUTICAL DESIGN. 2007;13(10):1053-1068
Restoring the dysfunctional endothelium
Osto E; Coppolino G; Volpe M; Cosentino F
Review: EUROPEAN HEART JOURNAL. 2007;28(1):88-136
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JRG; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Published conference paper: CLINICAL HEMORHEOLOGY AND MICROCIRCULATION. 2007;37(1-2):143-147
Aging and endothelial dysfunction
Cosentino F; Osto E
Editorial comment: CIRCULATION. 2006;114(24):f193-f194
Viewpoint: Climbing the academic ladder in Italy
Cosentino F; Francia P
Review: RECENTI PROGRESSI IN MEDICINA. 2006;97(12):711-718
[Vascular medicine: the near future].
De Sensi F; De Siati L; Cosentino F
Editorial comment: PANMINERVA MEDICA. 2006;48(1):1-2
Metabolic syndrome: current issues and perspectives.
Calò LA; Cosentino F; De Luca N
Editorial comment: MINERVA MEDICA. 2006;97(1):1-3
[Metabolic syndrome: current issues and perspectives].
Calò LA; Cosentino F; De Luca N
Review: HERZ. 2004;29(8):749-759
Diabetes and inflammation
Cosentino F; Assenza GE
Published conference paper: CIRCULATION. 2004;110(18):2889-2895
Deletion of p66^shc gene protects against age-related endothelial dysfunction
Francia P; Gatti CD; Bachschmid M; Martin-Padura I; Savoia C; Migliaccio E; Pelicci PG; Schiavoni M; Lüscher TF; Volpe M; Cosentino F
Published conference paper: CIRCULATION. 2004;110(1):91-96
Selective inhibition of protein kinase Cβ₂ prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells
Kouroedov A; Eto M; Joch H; Volpe M; Lüscher TF; Cosentino F
Review: CARDIOVASCULAR THERAPEUTICS. 2004;22(3):155-168
Pharmacological mechanisms of clinically favorable properties of a selective β₁-adrenoceptor antagonist, nebivolol
Kuroedov A; Cosentino F; Lüscher TF
Review: RECENTI PROGRESSI IN MEDICINA. 2003;94(10):444-450
[Statins in cardiovascular disease. Role of Rho/Rho kinase inhibition and of Akt activation ].
Cosentino F
Review: CIRCULATION. 2003;108(13):1655-1661
Diabetes and vascular disease - Pathophysiology, clinical consequences, and medical therapy: Part II
Lüscher TF; Creager MA; Beckman JA; Cosentino F
Review: CIRCULATION. 2003;108(12):1527-1532
Diabetes and vascular disease -: Pathophysiology, clinical consequences, and medical therapy:: Part I
Creager MA; Lüscher TF; Cosentino F; Beckman JA
Letter: CIRCULATION. 2003;108(10)
Effect of high glucose on vasculature -: Response
Cosentino F; Eto M; van der Loo B; Kouroedov A; Gatti CD; Joch H; Lüscher TF; De Paolis P; Volpe M; Bachschmid M; Ullrich V
Review: JOURNAL OF HYPERTENSION. 2003;21(7):1213-1220
Is it time to measure microalbuminuria in hypertension?
Volpe M; Cosentino F; Ruilope LM
Editorial comment: JOURNAL OF HYPERTENSION. 2003;21(3):501-503
Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy
Cosentino F; Francia P; Volpe M
Editorial comment: JOURNAL OF HYPERTENSION. 2002;20(9):1721-1724
Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions
Cosentino F; Volpe M
Published conference paper: JOURNAL OF HYPERTENSION. 2002;20(3):421-428
Nitric-oxide-mediated relaxations in salt-induced hypertension:: effect of chronic β₁-selective receptor blockade
Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
Review: JOURNEES ANNUELLES DE DIABETOLOGIE DE L'HOTEL-DIEU. 2002;:33-41
[Molecular mechanisms of endothelial dysfunction in diabetes].
Cosentino F; Luscher TF
Review: DRUGS IN R&D. 2002;3(5):311-323
Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.
Haller H; Cosentino F; Lüscher TF
Review: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2001;38:S3-11
Vascular effects of newer cardiovascular drugs:: Focus on nebivolol and ACE-inhibitors
Lüscher TF; Spieker LE; Noll G; Cosentino F
Published conference paper: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2001;38:S75-S78
Endothelial dysfunction and stroke
Cosentino F; Rubattu T; Savoia C; Venturelli V; Pagannonne E; Volpe M
Review: CURRENT HYPERTENSION REPORTS. 2001;3(1):79-88
Effects of blood pressure and glucose on endothelial function.
Cosentino F; Lüscher TF
Published conference paper: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2000;35(4 Suppl 2):S45-S48
Abnormalities of endothelial function in the pathogenesis of stroke: The importance of endothelin
Volpe M; Cosentino F
Editorial comment: CARDIOVASCULAR RESEARCH. 1999;43(2):274-278
Tetrahydrobiopterin and endothelial nitric oxide synthase activity
Cosentino F; Lüscher TF
Published conference paper: EUROPEAN HEART JOURNAL. 1998;19:G3-G8
Tetrahydrobiopterin and endothelial function
Cosentino F; Luscher TF
Review: DRUGS. 1998;55(4):509-517
The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal.
Lüscher TF; Cosentino F
Published conference paper: JOURNAL OF CLINICAL INVESTIGATION. 1998;101(7):1530-1537
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats
Cosentino F; Patton S; d'Uscio LV; Werner ER; Werner-Felmayer G; Moreau P; Malinski T; Lüscher TF
Published conference paper: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1998;32:S54-S61
Endothelial dysfunction in diabetes mellitus
Cosentino F; Lüscher TF
Review: CARDIOLOGIA. 1997;42(12):1221-1227
Endothelial function in coronary artery disease.
Cosentino F; Lüscher TF
Published conference paper: HYPERTENSION. 1997;30(4):817-824
Anatomic heterogeneity of vascular aging - Role of nitric oxide and endothelin
Barton M; Cosentino F; Brandes RP; Moreau P; Shaw S; Luscher TF
Published conference paper: CIRCULATION. 1997;96(1):25-28
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells
Cosentino F; Hishikawa K; Katusic ZS; Luscher TF
Show more

About me

Articles

All other publications

News from KI

Events from KI